Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | KCNJ1 | P48048 | 4/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8008660 | 0.90 | TSHR (0.56) | TSHRALDH1A1MAPTLMNAKDM4E | |
| SCHEMBL8934569 | 0.82 | TSHR (0.58) | TSHRALDH1A1MAPTKCNJ1KCNH2 | |
| SCHEMBL25600452 | 0.82 | ALDH1A1 (0.46) | ALDH1A1LMNAKMT2ACYP2C19HPGD | |
| SCHEMBL9911541 | 0.82 | KMT2A (0.55) | TSHRALDH1A1MAPTLMNAKMT2A | |
| SCHEMBL10434033 | 0.81 | ALDH1A1 (0.56) | TSHRALDH1A1MAPTLMNAKDM4E | |
| SCHEMBL135651 | 0.80 | TSHR (0.59) | TSHRALDH1A1MAPTKCNJ1KCNH2 | |
| SCHEMBL2850348 | 0.80 | TSHR (0.59) | TSHRALDH1A1MAPTLMNAKCNJ1 | |
| SCHEMBL5030925 | 0.79 | TSHR (0.58) | TSHRALDH1A1MAPTKCNJ1KCNH2 | |
| SCHEMBL7733298 | 0.79 | TSHR (0.58) | TSHRALDH1A1MAPTKCNJ1KCNH2 | |
| Hydrochloric Acid SCHEMBL5030930 | 0.79 | TSHR (0.58) | TSHRALDH1A1MAPTKCNJ1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238458-A1 | COMPOUNDS TARGETING FIBROBLAST-ACTIVATION PROTEIN AND METHODS OF USE THEREOF | PURDUE RESEARCH FOUNDATION | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238458-A1 | COMPOUNDS TARGETING FIBROBLAST-ACTIVATION PROTEIN AND METHODS OF USE THEREOF | FAP, FIBP, FGFR1 | TSHR 4225/4885ALDH1A1 2246/4885MAPT 3208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.